Siltuximab
Siltuximab is a pharmaceutical drug with 31 clinical trials. Currently 8 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
17
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
60.0%
12 of 20 finished
40.0%
8 ended early
8
trials recruiting
31
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Clinical Trials (31)
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia
Siltuximab in Schizophrenia
Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM
Treatment of COVID-19 Patients With Anti-interleukin Drugs
SILtuximab in Viral ARds (SILVAR) Study
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 31